Because of the important effects of CMTM4-related genes on prognosis and immunity in HCC patients, we used two immunotherapy cohorts to verify whether the combination of CMTM4 with PD-L1 could improve the prognosis of tumor patients underwent immunotherapy. This evidence concerns the gene CD274 and neoplasm.